BRCA1 and ovarian carcinoma: Regarding the role of IP therapy in BRCA-mutated ovarian cancer, an ancillary study of a subset of GOG 172 patients revealed that those with reduced BRCA 1 expression greatly benefitted from IP rather than IV chemotherapy: in tumors with aberrant BRCA1 expression the median OS was 84 months vs. 47 months in the IP vs. IV group, respectively (P = 0.0002)[39].